NEURELIS TO PRESENT ANALYSES OF VALTOCO® (diazepam nasal spray) CIV HIGHLIGHTING EFFECTS ON TIMING OF SEIZURES AT THE 35TH INTERNATIONAL EPILEPSY CONGRESS
Retrieved on:
Thursday, August 31, 2023
Online, Epilepsy, PM, International Bureau for Epilepsy, IBE, ASDS, World Organization of the Scout Movement, International League Against Epilepsy, Interval, Patient, Seizure, SAN, Post hoc analysis, IEC, Congress, FDA, ILAE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Treatment, Food, Diazepam, Pharmaceutical industry, Dietary supplement
SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in people with epilepsy for ages 6 to 65 at the 35th International Epilepsy Congress (IEC) in Dublin, Ireland, September 2 to 6. The congress is organized by the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE).
Key Points:
- The congress is organized by the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE).
- "Despite availability of chronic, daily oral medications to help control seizures, many patients continue to experience acute repetitive seizures," said Adrian L. Rabinowicz, M.D., Neurelis Chief Medical Officer.
- These data demonstrate that over a 12-month period, a statistically significant increase in the time between seizure clusters was observed with administration of diazepam nasal spray.
- This change in SEIVAL appears to be independent of age or changes in concomitant ASDs and may reflect a beneficial effect of intermittent rescue therapy with diazepam nasal spray.